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The complete amino acid sequence of major acute phase a,-protein of the rat (MAP) was derived from the 
nucfeotide sequence of cloned cDNA. Amino acid analysis and partial sequencing supported the predicted 
sequence. The amino acid compositions of MAP and rat low-M,kininogen are identical within experimentaf 
variation. The sequence is homologous (60%) to that of bovine low-M, kininogen and both proteins carry 
the sequence for the vasoactive nonapeptide bradykinin in their C-terminal region. The rate of synthesis 
of MAP and the levels of MAP mRNA change coordinately during the acute phase response to inflamma- 
tion. 
Major acute phase protein Bradykinin Kininogen Protein-biosynthesis regulation 
Acute phase reaction 
1. INTRODUCTION 3. RESULTS 
MAP is a glycoprotein whose concentration in 
rat serum increases about 20-fold during acute in- 
~~mation [l-3]. This increase is due to an in- 
crease in the synthesis rate in the liver [4]. MAP in- 
hibits proteinases with cysteine in their active cen- 
tre [S]. The data reported here suggest hat MAP 
has another important function during acute 
inflammation. 
in MAP &&!A 
A clone s~thesizing protein reacting with an- 
tibody against MAP was identified by expression- 
screening. The cDNA, excised from the plasmid 
with restriction endonuclease &I, had a size of 
about 1.4 kb. The sequencing strategy is sum- 
marized in fig. 1. The nucIeotide sequence and the 
deduced amino acid sequence are shown in fig.2. 
Residues 360-368 correspond to the sequence for 
bradykinin. 2. EXPERIMENTAL 
The preparation of a cDNA library from rat 
Iiver mRNA in pBR322, expression screening, 
nucleotide and amino acid sequencing, nick 
translation and dot hybridization were as described 
elsewhere [&lo]. 
Inflammation 
3.2. Partial amino acid sequencing of MAP 
MAP was cleaved into fragments by treatment 
with cyanogen bromide [9] or proteolytic enzymes. 
These fragments were then sequenced as described 
in [lo]. The reduced and carboxymethylated pro- 
tein was accessible to sequencing only after treat- 
ment with pyroghrtamate aminopeptidase [l I], in- 
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1 181 361 541 721 901 1081 1261 1441 
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Fig.1. Sequencing strategy for analysis of MAP cDNA. 
I . 
dicating that the N-terminus was glutamine. The 
sequences obtained, indicated in fig.2 by bold let- 
ters, agreed with those derived from the nucleotide 
sequence. 
3.3 Homology of MAP with low-M, kininogen 
A homology of 60% was found between MAP 
and bovine low-M, kininogen [12] (fig.3). In addi- 
tion, the amino acid composition of rat low-M, 
kininogen [13] agreed closely with that of MAP 
(table l), suggesting possible identity. 
3.4. MAP mRNA levels in liver and incorporation 
leucine into MAP during acute 
inflammation 
MAP cDNA was radioactively labelled by nick 
translation and used for measuring MAP mRNA 
levels by dot hybridization [8] in cytoplasmic ex- 
Table 1 
Amino acid composition (mol%) of MAP and rat plasma kininogen 
Amino acid MAP 
(from 131) 
MAP MAP Kininogen Kininogen 
(determined, (calculated from fraction A fraction B 
here) sequence, here) (from [ 131) (from [13]) 
Lysine 
Histidine 
Arginine 
Aspartic acid 
Threonine 
Serine 
Glutamic acid 
Proline 
Glycine 
Alanine 
Half-cysteine 
Valine 
Methionine 
Isoleucine 
Leucine 
Tyrosine 
Phenylalanine 
Tryptophan 
‘Cys + carboxymethyl-cys 
b22 h hydrolysis only 
8.1 8.6 1.5 1.4 7.7 
3.5 3.7 3.4 3.0 3.1 
3.4 3.3 3.4 3.0 3.0 
10.5 10.2 10.4 10.3 10.5 
1.4 7.8 1.5 7.3 1.5 
6.0 6.2 6.1 6.1 5.9 
13.0 12.9 12.6 13.2 13.3 
5.3 5.7 5.1 6.8 6.1 
6.7 6.6 6.3 6.3 6.7 
7.5 6.8 6.8 6.7 6.8 
1.0 3.5a 4.1 2.7 3.0 
7.1 5.8b 6.8 5.7 5.4 
1.4 1.1 1.2 1.2 0.6 
3.8 3.2b 4.1 3.7 3.7 
7.8 7.0 7.0 8.0 7.7 
3.0 3.0 3.2 4.3 4.4 
4.2 4.1 3.9 4.4 4.5 
0.6 0.6 0.5 not given not given 
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Leu Leu Cys SW Arg Leu Leu Pro Ser Leu Ala Gin Glu Glu Gly Ala 61n 61~ Leu Asn Cys Asn Asp Glu Thr Val 
GGGGGGGGGGGGGGTG CTC CTC TGC TCC AGG CTC CTG CCA AGT TTA GCG CAG GAA GAA GGC GCC CAG GAA TTG AAC TGC AAT GAT GAG ACT GTA 
10 20 30 40 50 60 70 80 90 
20 30 40 
Phe Gln Ala Val Asp Thr Ala Leu Lys Lys Tyr Asn Ala Glu Leu Glu Ser Gly Asn Gln Phe Val Leu Tyr Arg Val Thr Glu Gly Thr 
TTT CAG GCT GTG GAT ACT GCT CTG AAG AAA TAT AAC GCT GAG TTA GAA AGC GGC AAC CAG TTT GTG TTG TAC CGA GTG ACT GAG GGC ACT 
104 114 124 134 144 154 164 174 184 
50 60 70 
Lys Lys Asp Gly Ala Glu Thr Leu Tyr Ser Phe Lys Tyr Gln Ile Lys Glu Gly Asn Tyr Ser Val Gin Ser Gly Leu Thr Trp Gln Asp 
AAG AAG GAT GGC GCT GAA ACA TTG TAT TCC TTC AAG TAT CAA ATC AAG GAG GGC AAC TAC TCT GTT CAG AGT GGC CTC ACC TGG CAG GAC 
194 204 214 224 234 244 254 264 274 
80 90 100 
Cys Asp Phe Lys Asp Ala Glu Glu Ala Ala Thr Gly Glu Cys Thr Thr Thr Leu Gly Lys Lys Glu Asn Lys Phe Ser Val Ala Thr Gln 
TGT GAL TT;C$G GAC GCT2;4"" GAA GCC GCT ACT GGC GAA TGC ACA ACA ACT TTG GGG AAG AAA GAA AAT AAA TTC TCC GTA GCC ACC CAG 
304 314 324 334 344 354 364 
110 120 130 
Ile Cys Asn Ile Thr Pro Gly Lys Gly Pro Lys Lys Thr Glu Glu Asp Leu Cys Val Gly Cys Phe Gln Pro Ile Pro Met Asp Ser Ser 
ATC TGC AAT ATT ACT CCA GGT AAG GGT CCT AAG AAG ACA GAG GAG GAC CTC TGT GTC GGG TGT TTC CAA CCC ATA CCG ATG GAT AGC TCA 
374 384 394 404 414 424 434 444 454 
140 150 160 
Asp Leu Lys Pm Val Leu Lys His Ala Val Glu His Phe Asn Asn Asn Thr Lys HIS Thr His Leu Phe Ala Leu Arg Glu Val Lys Ser 
GAC CTG AAG CCT GTT CTG AAA CAC GCT GTG GAG CAT TTC AAC AAC AAC ACG AAG CAC ACC CAC CTC TTT GCT CTC AGA GAA GTA AAG AGT 
464 474 484 494 504 514 524 534 544 
170 180 190 
Ala HIS Ser Gin Val Val Ala Gly Uet Asn Tyr Lys Ile Ile Tyr Ser Ile Val Gin Thr Asn Cys Ser Lys Glu Asp Phe Pro Ser Leu 
GCC CAC TCA CAG GTG GTG GCT GGC ATG AAT TAT AAA ATT ATC TAC TCC ATT GTG CAA ACA AAT TGT TCA AAG GAG GAT TTT CCT TCC CTC 
554 564 574 584 594 604 614 624 634 
200 210 220 
His Glu Asp Cys Val Pro Leu Pro Tyr Gly Asp HIS Gly Glu Cys Thr Gly tlls Thr HIS Val Asp Ile His Asn Thr Ile Ala Gly Phe 
CAT GAA GA; ;GT GTA CCC6;;T CCC TAT $C GAT CAT GGi7GAG TGT ACG6;iT CAT ACC CAC GTG GAT AT;o;AT AAC ACA7;;T GCC GGC TTC 
4 4 4 694 724 
230 240 250 
Ser Gln Ser Cys Asp Leu Tyr Pro Gly Asp Asp Leu Phe Glu Leu Leu Pro Lys Asn Cys Arg Gly Cys Pro Arg Glu Ile Pro Val Asp 
TCA CAG AGC TGT GAC CTT TAT CCA GGA GAT GAT TTG ";,;A" CTA CTT CCC AAG AAT TGC CG7 GGC TGC CCC AGG GAG8;;A CCT GTA GAC 
734 744 754 774 784 794 814 
X0 270 280 
Ser Pro Glu Leu Lys Glu Ala Leu Gly HIS SW Ile Ala Arg Leu Asn Ala Gin HIS Asn His Ile Phe Tyr Phe Lys Ile Asp Thr Val 
AX CCG GAG CTG AAG GAG GCA CTT GGT CAT TCC ATT GCG AGA CTT AAT GCA CAG CAT AAC CAT ATT TTC TAT TTC AAG8;;T GAC ACC GTG 
824 834 844 854 864 874 884 904 
290 300 310 
Lys Lys Ala Thr Ser Gln Val Val Ala Gly Val Ile Tyr Val Ile Glu Phe Ile Ala Arg Glu Thr Asn Cys Ser Lys Gln Ser Lys Thr 
AAA AAG GCA ACA TCA CAG GTG GTT GCT GGA GTA ATA TAT GTG ATT GAG TTC ATA GCC AGA GAA ACT AAC TGT TCC AAGg;;A AGT AAA ACA 
914 924 934 944 954 964 974 994 
320 330 340 
Glu Leu Thr Ala Asp Cys Glu Thr Lys His Leu Gly Gin Ser Leu Asn Cys Asn Ala Asn Val Tyr Met At-g Pro Trp Glu Asn Lys Val 
GAA CT6 ACA GCG GAT TGT i;AG ACC AAA CAC CTC GGT CAA AGC CTC AAC TGC AAT GCT AAC GTG TAC ATG AGA CCT TGG GAG AAC AAA GTC 
1004 1014 1024 1034 1044 1054 1064 1074 1084 
350 360 ' 370 
Val Pro Thr Val Arg Cys filn Ala Leu Asp Met Met Ile Ser Arg Pro Pro Gly Phe Ser Pm Phe Arg Lw Val Arg Val Gln Glu Thr 
&CCG ACT GTC AGA TGC CAA GCA CTA GAT ATG ATG ATT TCT AGG CCT CCA GGA TTT TCA CCT TTC CGG CTG GTG CGA GTA CAA GAA ACT 
1094 1104 1114 1124 1134 1144 1164 1174 
380 390 400 
Lys Glu Gly Thr Thr Aq Leu Leu Asn Ser Cys Glu Tyr Lys Gly Aq Leu Ser Lys Ala Gly Ala Gly Pm Ala Pro Glu Aq Gln Ala 
JAA_GAA GGA ACG ACT AGG CTC CTA AAC TCA TGT GAG TAC AAG GGC AGA CTC TCA AAG GCA GGG GCA GGC CCA GCA CCT GAG CGT CAG GCA 
1184 1194 1204 1214 1124 1234 1244 1254 1264 
410 412 
Glu Ala Ser Thr Val Thr Pm 
GM GCT TCA ACC GTG ACA CCA TAGCCCGGCAAAGACCCGGAGTGGAAGGACCAGAAGACTCCTGGGATGTGTGCAGCATGGAAGCATGTTTCTTCATCACCTGATCCTGGGT 
1274 1284 1294 1304 1314 1324 1334 1344 1354 1364 1374 
iAAATAAAGTTCAGACTCGACGAGTTCAAAAAAAAAAAAAAACCCCCCCCCCCCCCCCCCCCCC 
1386 1396 1406 1416 1426 1436 
Fig.2. Nucleotide sequence of MAP cDNA and amino acid sequence of MAP. The nucleotide sequence derived from 
independent sequencing of both strands is indicated by underlining. Amino acid sequences derived from both nucleotide 
sequencing and direct analysis of MAP fragments are indicated by bold letters. Numbering of amino acids begins at 
the N-terminus of the mature protein. The bradykinin sequence is indicated by a box. 
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v KD s~q AATG q CT A T VA K RG N w KFsVA I q T c L ITP AE GP vv T APVE c L GC vH PI sm s p 0L E PvL RV A Iqv FNNNT s H s HLF 0 L 
170 180 190 200 210 220 230 240 
250 260 270 280 290 300 310 320 330 
Fig.3. Comparison of amino acid sequence of MAP and bovine low-M, kininogen. Identical sequences are indicated 
by boxes. The sequence for MAP is given in the upper line. Numbers refer to this sequence, including spaces (indicated 
by dots) which were introduced to optimize alignment. 
1 2 3 L 
DAYS AFTER TURPENTINE INJECTION 
Fig.4. MAP mRNA levels in liver during acute inflam- 
mation induced by subcutaneous injection of turpentine. 
MAP mRNA levels were determined by cytoplasmic dot 
hybridization [8]. Eight animals were used per time point 
and analyzed individually. Bars indicate standard errors. 
For comparison, incorporation of [‘4C]leucine into 
MAP, determined previously [3,4], is also given. MAP- 
mRNA levels, M; [14C]1eucine incorporation into 
MAP, o---o. 
tracts prepared from livers of rats at various times 
after inducing inflammation. The values obtained 
are depicted in fig. 4 together with the rates of in- 
corporation of [14C]leucine into MAP in serum 
determined previously [3,4]. The shapes of the two 
curves are similar, suggesting that regulation of the 
synthesis of MAP occurs at the mRNA level. 
4. DISCUSSION 
The reported data add new information to the 
understanding of both the structure and function 
of MAP. The complete nucleotide sequence now 
presented overlaps the N-terminal sequence 
reported by Anderson et al. [14]. Identification of 
the N-terminus of the mature protein (fig.2) by 
removal of cyclized glutamine establishes that 
MAP consists of 412 amino acids and is synthe- 
sized via a precursor protein, containin a preseg- 
ment of 18 amino acids ending with alanine, but no 
prosegment. Although MAP has been known for 
some time, its function is not fully understood. 
60 
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Esnard and Gauthier [5] described a plasma pro- 
tein (immunochemically identical with MAP [un- 
published]) which inhibited proteinases with cys- 
teine in their active centre, such as cathepsin H and 
L. The data reported here suggest hat MAP may 
also be a kininogen. If so, this kininogen would be 
an acute-phase reactant regulated at the mRNA 
level (fig.4). Release of the strongly vasodilating 
nonapeptide bradykinin may play a role in the 
mechanism of the inflammatory response. 
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